Markets Gone Wild

Pasithea Therapeutics Announces Comprehensive Settlement Agreement with the Camac Group MIAMI BEACH, Fla., Dec. 12, 2022 (GLOBE NEWSWIRE) Pasithea Therapeutics Corp. (Nasdaq: KTTA) Pasithea Therapeutics Corp., a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders, today announced that it has reached a comprehensive Settlement and…

Market movers: European stock exchanges closed the week mixed and with much uncertainty as they await this week’s central bank decisions. In addition, the publication in the early afternoon of producer prices in the United States (on a monthly basis at +0.3%, expectations for +0.2%) also raised fears for continued tightening of interest rates. Following…

TransUnion (TRU) Shareholder Notice: Contact Robbins LLP for Information About our Investigation San Diego, Dec. 12, 2022 (GLOBE NEWSWIRE) – Shareholder rights law firm Robbins LLP is currently conducting an investigation into TransUnion (NYSE: TRU) to determine whether certain officers and directors of the company have violated securities laws and breached fiduciary duties to shareholders….

The Impact of Voyager Digital Holdings Investor Losses Introduction Recently, Rosen Law Firm has issued a reminder to purchasers of Voyager Earn Accounts and VGX tokens about potential losses incurred between January 1, 2020 and November 9, 2022. This news has caused a stir among investors and raised questions about the security and reliability of…

Senti Bio Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting… Exciting Advances in Cell Therapy Have you heard the latest buzz from the ASH Annual Meeting? Senti Bio presented groundbreaking preclinical data on their innovative off-the-shelf CAR-NK cell therapy candidate, SENTI-202. This therapy is engineered with a logic-gated…

Agios Pharmaceuticals Presents Updated PYRUKYND® Data Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Agios Pharmaceuticals, Inc. is currently conducting Phase 3 ENERGIZE and ENERGIZE-T studies to evaluate the effectiveness of PYRUKYND® in adults with non-transfusion-dependent and transfusion-dependent α- or β-Thalassemia, respectively. This innovative drug has shown promise in improving outcomes for patients with these…

Unlocking the Potential: Kura Oncology Unveils Promising Clinical Findings at ASH Annual Meeting for Menin Inhibitor Ziftomenib in KOMET-001 Trial Description: – 30% CR rate at 600 mg in 20 patients with relapsed/refractory NPM1-mutant AML – Low frequency of differentiation syndrome, including 5% rate (1/20) of ≥ Grade 3 among NPM1-mutant patients treated at 600…

Welcome to Kaplan Fox & Kilsheimer LLP An Investigation into Silvergate Capital Corp Dec 09, 2022 Kaplan Fox & Kilsheimer LLP, a renowned law firm, is currently conducting an investigation on behalf of investors of Silvergate Capital Corp. The firm is looking into claims regarding Silvergate, listed on the New York Stock Exchange under the…